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METHODS: ORIGINAL ARTICLE
Random Insertion of mCherry Into VP3 Domain of 
 Adeno-associated Virus Yields Fluorescent Capsids With 
no Loss of Infectivity
Justin Judd1, Fang Wei1, Peter Q Nguyen2,4, Lawrence J Tartaglia3, Mavis Agbandje-McKenna3, Jonathan J Silberg2  
and Junghae Suh1
Adeno-associated virus (AAV)-derived vectors are promising gene delivery systems, and a number of design strategies 
have been pursued to improve their performance. For example, genetic insertion of proteins into the capsid may be used 
to achieve vector retargeting, reduced immunogenicity, or to track vector transport. Unfortunately, rational approaches to 
genetic insertion have experienced limited success due to the unpredictable context-dependent nature of protein folding and 
the complexity of the capsid’s macroassembly. We report the construction and use of a frame-enriched DNase-based random 
insertion library based on AAV2 cap, called pAAV2_RaPID (Random Peptide Insertion by DNase). The fluorescent mCherry 
protein was inserted randomly throughout the AAV2 capsid and the library was selected for fluorescent and infectious variants. 
A capsid site was identified in VP3 that can tolerate the large protein insertion. In contrast to previous efforts to incorporate 
fluorescent proteins into the AAV2 capsid, the isolated mCherry mutant maintains native infectivity while displaying robust 
fluorescence. Collectively, these results demonstrate that the pAAV2_RaPID platform library can be used to create fully 
infectious AAV vectors carrying large functional protein domains on the capsid.
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Introduction
Adeno-associated virus (AAV) is a small (20–25 nm), non-
enveloped, single-stranded DNA virus with an icosahedral 
(T = 1) 60-mer capsid formed from the assembly of three 
overlapping subunits VP1:VP2:VP3, typically in a 1:1:10 ratio. 
Its 4.7 kb nucleotide (nt) genome contains two open-reading 
frames (ORFs)—rep and cap—which encode overlapping 
protein sequences. Rep encodes four proteins responsible 
for viral genome replication, packaging, and site-specific inte-
gration into the S1 locus of human chromosome 19.1,2 Cap 
encodes the three structural proteins, VP1, VP2, and VP3. 
Assembly-activating protein, recently found in an alternate 
reading frame of the cap gene, mediates assembly of the VP 
proteins into the capsid before genome packaging occurs.3 
The primary cell surface receptors for AAV serotype 2 (AAV2) 
are heparan sulfate (HS) proteoglycans, while various core-
ceptors have been identified.4,5
AAV is being studied intensively for its utility as a safe 
and effective gene delivery vector. It transduces both divid-
ing and nondividing cells6 and elicits a comparatively mild 
adaptive immune response.7 Alterations to the virus capsid 
have been made to retarget native tropism,8–10 map the infec-
tion pathway,11 or evade host antibody detection.12–14 Capsid 
modifications can be achieved via genetic mutation,8 chemi-
cal conjugation,11,15,16 or noncovalent attachment.17 Of these 
approaches, genetic alterations have the advantages of 
relatively uniform end products, ease of production, reduced 
cost, and avoidance of potentially toxic synthetic chemicals.
Genetic modification of AAV has been attempted, includ-
ing insertion of cell-targeting peptides8 and fluorescent 
proteins.18,19 However, these rationally designed vectors 
have seen mixed success. For example, insertion of rela-
tively large fluorescent proteins into the AAV2 capsid has 
been limited to the N-terminus of VP2, resulting in viruses 
that are fluorescent but display decreased infectivity.8,18,19 
Labor intensive and costly mutagenesis studies have been 
employed to create maps of insertion-tolerant regions of 
the AAV capsid,9,20,21 but functional insertion varies widely 
even for similarly sized small peptides of different primary 
sequence at the same capsid location.21 Difficulties in 
genetic insertion of peptides/proteins into the AAV capsid 
likely arise from the unpredictable, context-dependent 
nature of protein subunit folding. Furthermore, in contrast 
to monomeric protein design, genetic insertion into AAV 
capsids must maintain efficient supramolecular assembly 
of the capsid, genome packaging, and dynamic conforma-
tional changes.22 Therefore, instead of purely rational design 
strategies, a high-throughput combinatorial method may be 
valuable to identify optimal insertion sites for the incorpora-
tion of desired peptides and proteins. In particular, a useful 
approach would be used to create highly diverse libraries 
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of capsid genes with randomly inserted peptides followed 
by selection/screening to identify virus variants with desired 
phenotypic properties.
A number of directed evolution approaches have been 
utilized to generate improved AAV vectors.10,14,23,24 For the 
random insertion of peptides/proteins, transposon-based 
mutagenesis has been used to build an AAV2 gene library 
with a hexahistidine motif inserted randomly throughout the 
cap ORF.25,26 However, no library mutants were isolated that 
conformed to the selective pressure—having both affinity for 
nickel while retaining infectivity. Alternatively, DNase-based 
random domain insertion is a useful complement to trans-
poson-based methods as it introduces additional sequence 
diversity through a range of deletions and tandem duplica-
tions (indels) at each site of insertion.27 Since accompany-
ing deletions have been shown in some cases to drastically 
improve the assembly of AAV insertional mutants,28 the 
additional indel sequence diversity may make DNase-based 
approaches more powerful. In addition, a DNase-based 
method was previously used to discover sites in the AAV5 
capsid permissive to deletions and duplications.29 To date, 
however, there have been no reports describing random 
insertion of large functional proteins into the AAV capsid.
In this study, we utilize a DNase-based random domain 
insertion strategy to build a modular, functionally enriched 
AAV2 capsid gene library named pAAV2_RaPID (Random 
Peptide Insertion by DNase). The platform library allows the 
insertion of a desired peptide/protein randomly throughout the 
VP3 region of AAV2. We demonstrate the utility and power of 
pAAV2_RaPID by isolating a virus variant with the mCherry 
gene genetically inserted into a capsid location never before 
tested for the insertion of relatively large protein domains. 
This mCherry-AAV2 hybrid vector maintains high genome 
packaging titer, wild type (wt)-like binding to heparin, displays 
robust fluorescence, and in contrast to previous attempts of 
inserting fluorescent proteins into AAV2, exhibits no loss in 
infectivity. Our pAAV2_RaPID library may be a useful tool to 
not only generate enhanced AAV vectors with modified func-
tionalities but to also uncover fundamental structure–function 
relationships of the AAV capsid.
Results
Construction of random insertion library
A library of AAV2 cap genes was constructed containing a 
modular DNA sequence randomly inserted into the VP3-
shared capsid structural domain (Figure 1a). The mCherry 
ORF30–which was used for selection and further study in this 
work–was chosen as a modular placeholder, since its size was 
large enough to permit size selection during library cloning. 
The mCherry placeholder was flanked by directional restric-
tion endonuclease sites (NgoM IV and Kas I) to allow efficient 
construction of other random insertion libraries by simple sub-
cloning procedures. The resulting DNA library was transformed 
into Escherichia coli and plated on selective media, yielding 
~5 × 106 individual colonies. After purification from E. coli, the 
plasmid library was resolved by agarose gel electrophoresis 
to isolate plasmid-mCherry hybrids containing a single insert 
(~30% of total band intensity) and to remove self-religated 
and non-cut plasmids. DNA sequencing analysis of individual 
clones from the size-selected gene library reveals insertions 
are dispersed throughout VP3, with deletions and duplications 
occurring at sites of mCherry insertion (Figure 1c). In addition, 
sequences were inserted in-frame at both cap-mCherry junc-
tions (upstream and downstream) in 12% of the sampled vari-
ants, similar to previous reports.27 Thus, a large parental library 
of cap genes was created with a modular DNA sequence ran-
domly inserted throughout the VP3 domain, which can be easily 
replaced with sequences encoding other peptides of interest.
Frame selection to enrich virus plasmid library
Since a limited number of AAV2 mutants can be selected 
for traits such as packaging and infectivity, we investigated 
whether the variants having mCherry out-of-frame from VP3 
could be removed from the parental gene library before per-
forming selection. To accomplish this, the ensemble of VP3-
mCherry gene fusions were subcloned into a derivative of 
pInSALect plasmid to create vectors that express our VP3-
mCherry hybrids as N-terminal fusions to β-lactamase.31 
Selection in E. coli was then performed to isolate in-frame 
VP3-mCherry variants. DNA sequencing analysis of clones 
from the “frame-selected” library revealed 100% in-frame 
VP3-mCherry gene fusions (n = 34) (Figure 1c). Further-
more, insertion sites within VP3 were dispersed throughout 
the VP3 ORF and did not correlate with secondary struc-
tural elements, suggesting frame enrichment was unbiased. 
The frame-selected pool of VP3-mCherry gene fusions was 
subcloned into an AAV2 expression vector, yielding the final 
enriched, modular library pAAV2_RaPID (Figure 1b).
Collectively, our results show that we have generated a 
highly diverse combinatorial library with a modular linker 
sequence randomly inserted throughout the VP3 region of 
the cap gene. In contrast to transposon-based libraries, the 
pAAV2_RaPID library contains additional diversity through 
deletions and duplications of varying sizes, which may be use-
ful in identifying additional phenotypic functionality.27 Simple 
and efficient subcloning of alternate inserts can be achieved 
through the use of the directional NgoM IV and Kas I sites. Fur-
thermore, the frame-enriched pAAV2_RaPID library increases 
the number of in-frame variants that can be included in phe-
notypic selection schemes that are limited in population size. 
Ultimately, this may lead to more effective directed evolution 
experiments when using random domain insertion in AAV.
Selection and high-throughput screening for fluorescent 
AAV2-mCherry hybrid
As a demonstration of the utility of the pAAV2_RaPID library, 
we sought to identify sites in the VP3 domain of the AAV2 
capsid protein that would tolerate insertion of a large pro-
tein domain but retain the ability to form infectious capsids. 
mCherry was chosen as a model insertion because of its 
comparatively large size (26.7 kDa, ~45% the size of VP3), 
proximity of its N- and C-termini,32 potential utility in virus-traf-
ficking studies,18,19,33 and it can be selected via fluorescence-
activated cell sorting (FACS).
We reasoned that the probability of finding successfully 
assembled, infectious virions carrying the mCherry protein 
would be inversely proportional to the copy number of mCherry 
per capsid. Therefore, we used a capsid mosaic approach34 in 
which the pAAV2_RaPID gene library was used to produce a 
pool of AAV2 hybrids with mCherry randomly inserted in the 
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VP3 region of VP1 only. To achieve this, VP2/VP3 expression 
was ablated from the pAAV2_RaPID library by knocking out 
the major splice acceptor site of the cap gene.35 Thus, during 
virus production, only VP1-mCherry hybrids are expressed 
from the pAAV2_RaPID library. Wt VP2 and VP3 proteins 
were expressed in trans to allow complete assembly of the 
mosaic virions with all three VP proteins (VP1-mCherry, VP2, 
VP3). To facilitate Darwinian evolution during selection, the 
AAV2 inverted terminal repeat (ITR) sequences were placed 
in cis with RaPID genomes containing the VP1-mCherry 
gene library (Figure 2), but left absent from the wt VP2/VP3 
genes. Therefore, VP1-mCherry containing capsids will pack-
age their respective hybrid genomes, resulting in a pheno-
type (infectivity and fluorescence) and genotype (mCherry 
insertion site within VP1) link.
A selection scheme was devised to isolate fluorescent 
AAV2-mCherry hybrids that retain infectivity in HEK-293T cells 
(referred to hereinafter as 293T cells) (Figure 2, see Methods); 
293T cells were infected with the mosaic AAV2-mCherry virus 
library and coinfected with adenovirus to amplify successfully 
infectious AAV2-mCherry hybrids. Cells positive for mCherry 
fluorescence were then isolated via FACS.
Infection by the naive virus pool yields a low percentage 
of mCherry-positive cells (<0.005%) as determined by FACS 
and epifluorescence microscopy (Figure 3a). Overall, 1,460 
mCherry-positive cells were sorted in the first round. Interest-
ingly, sampling of 10 clones after selection revealed a domi-
nant wt population (data not shown). The minority mutant 
fraction, containing the randomly inserted mCherry ORF, was 
recovered by cloning an ampicillin resistance cassette into 
Figure 1 Construction of pAAV2_RaPID, a modular, enriched random domain insertion library. (a) The random insertion library was 
constructed by brief DNase I treatment of a plasmid containing the cap gene, resulting in a library of randomly linearized vectors. After blunting 
by T4 DNA polymerase, a modular linker (mCherry ORF) flanked by unique RE sites, NgoM IV and Kas I, encoding small amino acids alanine-
glycine and glycine-alanine respectively, was ligated blunt-wise into the library. The resulting cap-insert hybrids were size selected by excision 
and purification using agarose gel electrophoresis, resulting in a library of capsid genes with a randomly inserted linker. These genes were 
then enriched for in-frame variants using a pInSALect derivative.31 The enriched gene pool was cloned into the VP3 portion (between Nco I and 
BfuA I sites) of an AAV2 expression vector, yielding the pAAV2_RaPID library. (b) A scaled diagram of the pAAV2_RaPID library illustrates an 
array of random deletions/duplications at insertion sites of mCherry–shown below with flanking RE sites NgoM IV and Kas I–throughout the 
VP3 ORF. The hairpin loops represent the ITRs (not drawn to scale) and ∆Cap ind icates the region of cap deleted from the vector into which 
the library genes were cloned. Start codons of capsid proteins VP1, VP2, and VP3 are indicated by bent arrows. Nucleotide numbering used 
in this study is shown, starting with 1 at the adenosine of the VP1 start codon, continuing with 607 at the adenosine of the VP3 start codon 
(at a Nco I site), and ending with 2205 at the final nucleotide of the TAA stop codon (next to a BfuA I cut site). (c) Scaled representation of 
insertions found in sequenced clones from the pAAV2_RaPID library, aligned with the VP3 ORF (light gray arrow, nucleotide positions in VP1 
numbering). Arrows indicate both the direction of insert and size of deletion for each clone in the library before (upper, dark gray) and after 
(lower, black arrows) frame selection. *Indicates a duplication. The one-dimensional scatter plot shows the distribution of all crossover sites 
(upstream and downstream, naive and enriched). Below, structural features of VP3 are illustrated with arrows (sheets) and cylinders (coils). 
AAV, adeno-associated virus; ITR, inverted terminal repeat; ORF, open-reading frame; RE, restriction endonuclease.
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the upstream NgoM IV linker site, an restriction endonuclease 
site not present in wt genes (Supplementary Figure S1) fol-
lowed by selection in E. coli. After enrichment, sampling of 
the gene pool returned 100% mutant sequences. Sequenc-
ing of 10 variants from the selected gene pool after round 
1 identified two clones (r1c3, r1c10) with mCherry inserted 
into hypervariable region 5 (HVR5) of VP1.36 r1c3 contains 
mCherry in place of the deleted amino acid sequence 453-
GTTTQSR (VP1 numbering), and r1c10 contains a similar 
deletion: 452-SGTTTQSR.
Subsequent rounds of selection resulted in an increased 
mCherry-positive frequency in FACS measurements 
(~0.04%). However, sequencing of selected RaPID variants 
indicated convergence on large deletions at sites of insertion 
in VP1, averaging 488 amino acids by the third round (data 
not shown). Thus, under the given selection pressures, the 
virus gene pool appears to have reached its optimum after 
the first round of selection.
Detection of mCherry in capsid of selected clone r1c3
The two selected clones harboring mCherry within HVR5 of 
VP1 differ by only one deleted residue, so we focused on char-
acterizing the properties of only one of these mutant clones, 
r1c3. Western blot analysis of the purified mutant indicates 
wt-like stoichiometric incorporation of the VP1-mCherry pro-
tein into the virus capsid (Figure 4a). Several additional pro-
tein bands are observed that stain positive for mCherry and 
VP-specific antibodies, suggesting either mild proteolysis or 
alternate translation, but the full-length VP1-mCherry protein 
appears to be the dominant VP1 species. To detect the pres-
ence of mCherry directly on assembled virus capsids, we 
used immunoelectron microscopy to obtain high resolution 
images of the AAV2-mCherry virions (Figure 4b). Immunos-
taining of r1c3 with a polyclonal mCherry antibody resulted 
in successful labeling of the capsid. Wt AAV2 capsid control 
samples were not labeled under identical conditions. These 
results provide two lines of direct evidence that mCherry is 
incorporated into the VP1 subunit and is displayed on the 
capsid surface of the r1c3 clone.
mCherry-capsid hybrids display wt-like infectivity and 
robust fluorescence
To establish how mCherry insertion influences the functional 
properties of AAV2, we characterized the binding and infec-
tivity of the mosaic capsids built using the mCherry-VP1 
hybrid r1c3. First, we evaluated the binding affinity of r1c3 
for its primary cell surface receptor, HS proteoglycans, using 
heparin-sepharose column chromatography (Figure 4c). 
Figure 2 Selection for fluorescent VP1-mCherry hybrids. 
(i) The pAAV2_RaPID library was used to produce a pool of AAV2 
hybrids with mCherry inserted in the VP3 region of VP1 only, which 
contains the PLA2 domain required for infectivity; wt VP2/3 genes 
were supplemented in trans. (ii) A monolayer of HEK-293T cells were 
infected with the virus pool. (iii) Successfully infectious variants were 
then rescued by superinfection with Ad5. (iv) Cells were harvested and 
sorted by FACS to isolate those expressing fluorescent VP1-mCherry 
proteins. (v) DNA was extracted from the sorted cells, amplified by 
PCR, and subcloned back into the VP1 expression vector, generating 
an enriched library gene pool. The selection procedure was iterated 
twice more using the enriched gene pools for a total of three rounds 
of selection. FACS, fluorescence-activated cell sorting.
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Figure 3 Screening of fluorescent VP1-mCherry hybrids isolated after one round of selection. (a) FACS data from round 1 selection. 
Y-axis indicates the mCherry signal in relative fluorescence units (RFU). X-axis represents cell autofluorescence in the green spectrum. Gate 
in upper left quadrant defines the region where cells were collected during selection. (b) Clones recovered after the first round of selection are 
illustrated as in Figure 2. Each clone is represented by a red arrow that indicates the region of VP3 deleted at the site of mCherry insertion. 
Clone r1c3 is marked with an asterisk. A similarity plot is shown below, indicating the regions of VP3 that are conserved across AAV serotypes 
1-12, generated from an alignment in Vector NTI. Bar at left indicates percent similarity. Note r1c3 lies in a wide valley of the similarity plot 
located at the GH2/3 loop. AAV, adeno-associated virus; FACS, fluorescence-activated cell sorting.
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Affinity of AAV2 for heparin is correlated with the salt con-
centration required to disrupt ionic interactions, thus eluting 
virions from the heparin column. Our results indicate the 
mutant retains wt-like affinity for heparin, since both samples 
display similar elution profiles with peak fractions near 500 
mmol/l NaCl.
To determine whether mutant r1c3 particles are able to bind 
cells and become internalized, the mosaic virus was added to 
a monolayer of HeLa cells (Figure 5). Confocal microscopic 
examination reveals a punctate mCherry signal throughout 
the cytoplasm, indicating successful internalization and fluo-
rescent properties of the VP1-mCherry hybrid capsid.
To compare the infectivity of mosaic capsids containing 
the AAV2-mCherry hybrid with native AAV2 capsids, the 
r1c3 capsid was packaged with a cytomegalovirus-green 
fluorescent protein (GFP) transgene reporter and applied to 
HeLa cells, followed by flow cytometric analysis. As a control, 
virions assembled from VP2 and VP3 only were packaged 
with the identical GFP reporter (VP2/3-GFP) and applied at 
the same multiplicity of infection (MOI). As expected, negli-
gible fluorescence was detected by flow cytometry for the 
VP2/3-GFP virions (Figure 6; Supplementary Figure S2). 
Remarkably, the r1c3 VP1-mCherry hybrid fully restored 
infectivity of the VP2/3 particles to levels comparable to wt. 
Collectively, our results indicate the r1c3 mutant maintains 
wt-like affinity for heparin, is internalized into cells in vitro, 
and displays robust mCherry fluorescence with no loss of 
infectivity.
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Figure 4 Physical characterization of r1c3. (a) Western blot analysis of clone r1c3. Staining with B1 (left panel), which binds the C-terminus of 
VP1/VP2/VP3, shows a typical pattern for wt AAV2. In comparison, B1 staining shows normal VP2/VP3 expression for r1c3 with a higher molecular 
weight VP1-mCherry hybrid protein (closed circles), confirmed by mCherry (mCh) and A1 staining (middle and right panels, respectively). A 
fragment sized similarly to wt VP1 was also seen in r1c3 by B1 staining (open circles; left panel), but appears positive for mCherry staining (middle 
panel). In addition, r1c3 showed a lower molecular weight band (closed triangles) with B1 and mCherry staining that was negative for A1, likely 
a C-terminal proteolytic fragment. These and additional bands in the blots may indicate mild proteolysis of r1c3, but the full-length VP1-mCherry 
chimera appears to be the dominant VP1 species. (b) Immunoelectron microscopy of r1c3 demonstrates incorporation of the VP1-mCherry 
protein into the capsid. Transmission electron micrographs were taken after staining with a polyclonal mCherry antibody followed by a secondary 
antibody conjugated to gold nanoparticles (12 nm, black dots). Wt AAV2 is shown at right under identical staining conditions. Mutant r1c3 is shown 
as an empty (left panel) and full (middle panel) capsid, both containing VP1-mCherry chimeric proteins. Bar = 20 nm. (c) Affinity chromatography 
shows r1c3 retains affinity for heparin, the primary cell surface receptor for AAV2. qPCR analysis (top panel) of eluates with increasing NaCl 
show wt AAV2 (black bars) and r1c3 (gray bars) both elute in peak fractions near 500 mmol/l NaCl. Error bars indicate SD from three (wt) or two 
(r1c3) independent experiments. Western blot analysis (bottom panel) of samples run under non-reducing conditions, stained with B1, verifies 
presence of capsid subunits in elutions. AAV, adeno-associated virus; qPCR, quantitative PCR.
Figure 5 Mosaic AAV2-mCherry mutant r1c3 is fluorescent and 
internalizes into HeLa cells. HeLa cells were infected at a MOI of 
7 × 105 vg/cell for 6 hours at 37 °C, fixed and stained with DAPI. The 
negative control (left column) is cells only. Confocal imaging reveals 
a punctate signal in the mCherry emission spectra (red) throughout 
the cytoplasm. DAPI (blue) marks cell nuclei. Bar = 10 μmol/l. AAV, 
adeno-associated virus, DAPI, 4′,6-diamidino-2-phenylindole; MOI, 
multiplicity of infection; vg, vector genome.
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Structural modeling of mCherry-capsid hybrids
To visualize the theoretical structure of the mCherry-capsid 
hybrid, molecular modeling was performed (Figure 7). Based 
on modeling analysis and prior studies of the GH2/3 loop,9,21,37 
the structural effects of insertion into HVR5 (surface loop IV) 
on the capsid should be tolerated.38 This loop is on the sur-
face of the capsid at the tips of the threefold protrusions that 
extend from the surface of the AAV capsid. Interestingly, the 
positioning of mCherry on the AAV2 capsid in the r1c3 model 
containing randomly placed mCherry-cap hybrid subunits 
(Figure 7c) bears a remarkable resemblance to the immuno-
electron micrographs of this mutant (Figure 4b).
Discussion
We have built a modular, diverse AAV2 capsid gene platform 
library, named pAAV2_RaPID. Preselection of pAAV2_RaPID 
for in-frame insertions was performed to allow for more effi-
cient screening of functional variants (see Supplementary 
Discussion). This may be critical in future applications where 
additional sequence complexity is desired in the random 
insertion library. For example, randomized linkers connecting 
cap and heterologous sequences may improve tolerance 
of difficult insertions or facilitate allosteric regulation of viral 
behavior by inserted domains.27 Using this library, a DNA 
sequence encoding a desired peptide can be quickly and 
efficiently inserted randomly throughout the AAV2 cap gene. 
Selection can then be performed to identify insertion location 
and deletion/duplication combinations that are optimal for the 
proper functioning of the desired peptide.
Using infective selection on 293T cells and FACS, we suc-
cessfully isolated a novel mutant, r1c3, containing a functional 
mCherry protein genetically inserted into the VP3 domain 
of the capsid protein VP1. All previous reports indicate that 
genetic incorporation of large proteins, including GFP, into the 
AAV2 capsid interferes with infectivity significantly.8,18,19 Thus, 
the preservation of native infectivity in r1c3 is a substantial 
finding. Since AAV-trafficking patterns have been shown to be 
vector dose-dependent,39 the use of improved fluorophore-
tagged AAV vectors such as r1c3 may help identify infection 
pathways at lower MOI, which may be more clinically relevant. 
Furthermore, encoding of large protein domains in general 
in the GH2/3 loop may offer improved vector performance 
such as in luciferase-displaying AAV vectors useful for in vivo 
tracking applications.40 Although other approaches to gener-
ate labeled AAV capsids have been demonstrated, genetic 
incorporation offers several advantages, such as ease of pro-
duction, reduced cost, and higher purity.19
The library selection scheme used in this work takes 
advantage of a mosaic capsid approach in order to accom-
modate the large mCherry protein on the capsid while main-
taining genome packaging and infectivity. VP1 was selected 
to harbor the randomly inserted mCherry throughout the 
VP3-shared region, since it is required for infectivity (Figure 
6b).41 With the emergence of large deletions in the first round 
of selection (Figure 3b) and convergence in later rounds, 
the pressure to assemble genome-containing VP1-mCherry 
hybrids may have been counteracted by the requirement to 
maintain the genome packaging limit of AAV2 (~5.2 kb).42 
Recovery of oversized clones such as r1c3 may have been 
due to the packaging of partial genomes containing the full-
length cap gene.42 Isolation of viral clones with large genome 
deletions suggests the inclusion of wt VP2/VP3 in trans may 
have been sufficient to rescue defunct library genes dur-
ing production, as VP2/VP3 alone are capable of assembly 
and packaging and have marginal infectivity (Figure 6a).41 
Although this directed evolution study was successful at iden-
tifying a functional mutant, r1c3, the selection scheme used 
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flow cytometry (in b). The incorporation of VP1-mCherry in r1c3-
GFP completely recovers infectivity compared with wt, while VP2/3 
only virions display negligible transduction. Each transduction was 
performed in triplicate (n = 3), with error bars indicating SD. *P 
value <0.001. Bar = 10 μmol/l. GFP, green fluorescent protein; MOI, 
multiplicity of infection.
a b c
Figure 7 Molecular model of AAV2-mCherry hybrid r1c3. (a) VP3 
(green) with inserted mCherry (red) as a monomer; symmetry axes 
are labeled as triangle (threefold), pentagon (fivefold), and oval 
(twofold). (b) A special pentamer in the context of the capsid (blue) 
showing the VP3-mCherry subunit in green-red. (c) A ribbon diagram 
showing five VP1-mCherry monomers randomly placed in the context 
of the capsid (blue). AAV, adeno-associated virus.
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here may be improved in future studies by reduction of the 
total AAV2 genome size. For example, this may be achieved 
by deleting portions of rep in library genomes and delivering 
full-length rep copies in trans during replication, potentially 
helping to balance the selective pressures in favor of func-
tional VP1 hybrids. Furthermore, domination of the library 
population by wt cap genes after the first round of selection 
was likely due to the advantage in reproductive fitness of wt 
over the average library member. Although recombination 
with VP2/3 plasmids cannot be ruled out, it is unlikely this 
plays a dominant role since later rounds of selection did not 
return any wt cap genes.
Despite the occurrence of off-target selective pressures, 
two successful clones, r1c3 and r1c10, were isolated after 
just one round of selection. Mutant r1c3 was chosen for fur-
ther analysis because the insertion was located in a region 
of low-sequence homology with serotypes 1-12, known as 
HVR5,36 located in the GH2/3 loop.43 Though this region 
is known to tolerate mutation,21,44 insertion of a large pro-
tein domain has not been demonstrated previously. To our 
knowledge, the largest protein successfully inserted into any 
VP3-shared crystallized region of the AAV2 capsid protein 
has been limited to the 34 amino acid Z34C immunoglobulin-
binding domain inserted into the GH12/13 loop.28 Interest-
ingly, the packaging efficiency of this mutant was improved 
an order of magnitude by deleting 9 amino acids (581-589) 
at the site of insertion. This previous result corroborates the 
utility of our DNase-based random insertion library method 
as demonstrated here, where deletions of various sizes nor-
mally accompany insertions and can improve tolerance to 
heterologous domains. Later work from Gigout et al.45 dem-
onstrated a mosaic approach to incorporate the Z34C peptide 
with improved packaging efficiency. In our work, we confirm 
the utility of mosaic capsid approaches in combination with 
random insertion by inserting a significantly larger protein by 
almost an order of magnitude: mCherry (240 aa) versus Z34C 
(34 aa). Taken together, our pAAV2_RaPID library approach 
identified the GH2/3 loop of the AAV2 capsid as a region tol-
erant to protein domains of size in magnitude not previously 
demonstrated.
Binding of HS proteoglycans is an important event in the 
life cycle of AAV2, as it has been shown to induce conforma-
tional changes in the capsid structure46 and is the primary cell-
binding step during infection.4 Although the main HS-binding 
region on the capsid sits in the valley between the threefold 
spikes,5 directly below the inserted mCherry protein, r1c3 
retains high affinity for heparin (Figure 4c). This result is con-
sistent with the length and flexibility of HS chains, facilitating 
access to capsid-binding sites in the presence of potential 
sterically obstructive mCherry appendages. Alternatively, HS 
interactions with HS-binding domains on the virus capsid that 
are free of mCherry may be sufficient to achieve wt affinity, 
in agreement with the reported non-linearity of HS binding by 
mosaic capsids composed of varying ratios of capsid subunits 
from HS-positive and HS-negative serotypes.47 Furthermore, 
the folding of mCherry and its linking sequences may provide 
enough flexibility or steric access to allow unimpeded interac-
tions with HS-binding sites, as supported by the model (Fig-
ure 7). Remarkably, r1c3 maintains full infectivity similar to wt 
AAV2 capsids. This result suggests that the AAV2-mCherry 
hybrid may also maintain wt interactions with its coreceptors 
and follow a similar intracellular pathway, although we cannot 
rule out at this time that r1c3 may follow an alternative intra-
cellular pathway with similar efficiency. Overall, the retention 
of wt-like heparin binding and infectivity by the VP1-mCherry 
hybrid virus is a clear demonstration of the potential utility 
of our pAAV2_RaPID library for constructing virus nanopar-
ticles with large protein VP hybrids.
In summary, we have constructed a modular, diverse, and 
enriched random insertion library, pAAV2_RaPID. The library 
can be used for the facile insertion of desired peptide domains 
randomly throughout the AAV2 capsid gene, followed by 
selection/screening for optimal sites. We demonstrated the 
utility of the pAAV2_RaPID library by identifying a novel 
mCherry-AAV2 hybrid containing the largest reported protein 
insertion in the VP3 domain. Strikingly, in addition to produc-
ing high titers, the hybrid virus vector retains full infectivity 
and displays robust fluorescent properties. This fluorescently 
labeled AAV2 variant may prove useful in further elucidat-
ing mechanisms of viral infection and pave the way for the 
combination of imaging and therapy in AAV- mediated gene 
delivery. Furthermore, the successful insertion of mCherry 
into the surface of the AAV2 capsid without affecting virus 
infectivity has important implications for future vector design 
with other protein domains once thought too large to incor-
porate into AAV.
Materials and methods
Plasmids. pRepCap was created by subcloning the AAV 
genome (without ITRs) from pSub201 into a pBlueScript SK 
II (+) backbone using Xba I. The plasmid vector was then sub-
jected to site-directed mutagenesis to remove existing Kas I, 
NgoM IV, Nco I, and BfuA I (RaPID restriction sites) restriction 
sites with silent mutations. The VP3 start codon was mutagen-
ized to produce a Nco I site and a BfuA I site was inserted just 
downstream of the stop codon, yielding pRepCap_RR (RR: 
RaPIDready). The modified genome was then subcloned into 
pSub201∆NgoMIV (pSub201 with the NgoM IV site removed 
from the vector backbone) using Xba I sites to regain the ITRs, 
yielding pSub201_RR. To create the pAAV2_RR expression 
vector, the entire modified genome (with ITRs) was then cut 
from pSub201_RR using Pvu II, and ligated to the pET28a(+) 
backbone between the Pvu II and Xmn I sites. To generate 
pAAV2_RR∆cap, pSub201_RR was digested with BsiW I and 
Xcm I, blunted with T4 DNA polymerase and religated. The 
partially deleted cap gene was then subcloned into pAAV2_
RR using Nco I and BfuA I sites. pMIN_VP3 was created by 
excising VP3 from pRepCap_RR using Nco I and BfuA I sites, 
and ligating to a minimized plasmid backbone generated by 
sequence overlap extension48 using pBAD24 as a template. 
pInSALect_RR was created by removal of RaPID restriction 
sites from pInSALect, followed by insertion of Nco I and BfuA I 
sites between the intein sequences. Mosaic expression vectors 
were constructed as previously described. Briefly, pAAV2_RR 
was mutagenized to knock out the major splice acceptor site 
downstream of the VP1 start codon, giving VP1-only expres-
sion vector pAAV2_VP1_RR. For wt VP2/VP3 expression, 
pRC_RR was mutagenized to knock out the VP1 start codon, 
yielding pRC_RR_VP2/3.
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RaPID library construction. pMIN_VP3 was digested with dilute 
DNase I (New England Biolabs, Ipswich, MA) in 1 mmol/l MnCl2, 
resulting in a pool of randomly linearized plasmids. This pool 
was resolved by agarose gel electrophoresis with a restriction 
endonuclease-linearized control to identify the near full-length 
linearized fraction, which was excised and purified using a 
Zymoclean Gel DNA recovery kit (Zymo Research, Irvine, CA). 
The randomly linearized pool was then blunted with T4 DNA 
polymerase and dephosphorylated with T4 Polynucleotide 
Kinase (NEB, Ipswitch, MA). The mCherry ORF was amplified 
by sequence overlap extension48 to remove Nco I and Kas I 
sites and to add an NgoM IV site upstream and a Kas I site 
downstream of the coding sequence. Pfu DNA polymerase was 
used for mCherry amplification to generate blunt ends, allow-
ing ligation to the linearized pool of cap genes. Transformation 
into DH10β E. coli (Life Technologies, Grand island, NY) was 
followed by amplification on agar plates, and purification using 
a Zyppy Plasmid Miniprep Kit (Zymo Research, Irvine, CA). 
The resulting plasmid library was then size-selected by aga-
rose gel electrophoresis to enrich the single insert-containing 
fraction (Supplementary Figure S1). The size-selected naive 
pool was then subcloned into pInSALect_RR using Nco I and 
BfuA I restriction sites, followed by three rounds of selection on 
agar containing carbenicillin (100 μg/ml) and chloramphenicol 
(50 μg/ml). The frame-selected plasmid pool was purified and 
the mutant cap genes were subcloned into pAAV2_RR∆cap 
using Nco I and BfuA I sites to create pAAV2_RaPID. The VP1 
only library, pAAV2_VP1_RaPID was created by cloning the 
VP3 library from pAAV2_RaPID into VP1-only expression vec-
tor pAAV2_VP1_RR∆cap using Nco I and BfuA I.
Virus production. The AAV2_RaPID_mCherry virus librar-
ies were generated by linear polyethyleneimine-mediated 
(molecular weight 25 kD) triple transfection of pAAV2_VP1_
RaPID_mCherry (10 ng), pRC_RR_VP2/3 (5 μg), and pXX6 
(25 μg) into each of 10 × 15 cm poly-l-lysine–coated plates of 
70% confluent 293T. The cells were harvested 46–48 hours 
post-transfection, lysed by three cycles of freeze/thaw in 1% 
protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO) and 
treated with 4 U/ml Benzonase (Sigma-Aldrich) for 30 minutes. 
The lysate was then clarified by centrifugation and loaded onto 
an iodixanol step gradient (15/25/40/54%) in Beckman Ultra-
Clear QuickSeal Tubes (Beckman Coulter, Brea, CA). The 
lysate was resolved by centrifugation at 48,000 rpm for 1.75 
hours in a 70Ti rotor, and the purified virus library extracted 
from the 40% layer. The genomic titer was determined by qPCR 
using SYBR green (Life Technologies) and primers against rep 
(forward: AGGACCAGGCCTCATACATCTC, reverse: TGTCC 
AAGGCAGCCTTGATT) on a BIO-RAD CFX96. Clonal pro-
duction of r1c3 packaged with its genome for transmission 
electron microscopy studies was performed similarly using 
pAAV2_VP1_RaPID_r1c3 (2 pmol), pRC_RR_VP2/3 (2 pmol), 
and XX6 (2 pmol). For confocal and transduction studies, r1c3 
was packaged with a GFP transgene. Its genome was cloned 
into pBlueScript SK II (+) using Xba I to remove ITRs, gener-
ating pRC_RR_VP1_r1c3; 293T cells were then transfected 
as above with pRC_RR_VP1_r1c3 (1 pmol), pRC_RR_VP2/3 
(1 pmol), pAAV_GFP (containing a cytomegalovirus-GFP 
reporter flanked by AAV2 ITRs) (1 pmol), and XX6 (1.65 pmol) 
and purified as above. Virus titers were quantified via qPCR 
using primers against the cytomegalovirus promoter in the 
GFP transgene cassette (forward: TCACGGGGATTTCCAA 
GTCTC, reverse: AATGGGGCGGAGTTGTTACGAC).
Virus selection. The virus library was applied to 70% conflu-
ent 293T cells at a MOI of ~10 viral genomes per cell. Four 
hours after infection, the library was rescued with adenovirus 
serotype 5 at an MOI of ~10 IU/cell; 48 hours post-infection, 
the cells were harvested by trypsinization, pelleted and resus-
pended in phosphate-buffered saline (PBS) (5 mmol/l EDTA). 
The cells were then filtered through a 40 μmol/l cell strainer 
(BD, Franklin Lakes, NJ) and sorted using a DakoMoFlo cell 
sorter. mCherry-positive cells were lysed by three cycles of 
freeze/thaw and purified using a Zyppy Plasmid Miniprep Kit 
after adding 1 μg of salmon sperm DNA as a carrier. Cap 
genes were amplified by PCR using a Roche Expand Hi-Fi-
delity PCR kit (Roche, Indianapolis, IN) and subcloned into 
pAAV2_VP1_RR∆cap using Nco I and BfuA I.
Western blot. Virus samples were resolved in 4–12% or 12% 
Bis-TrisNuPAGE gels (Life Technologies) and transferred to 
nitrocellulose (GE Healthcare, Pittsburgh, PA) at 40 V for 90 
minutes, otherwise following manufacturer guidelines. Gels 
were run under reducing conditions, except for the heparin 
fractions (Figure 4). Blocking was performed in 5% skim milk 
in PBS with 0.1% Tween-20 (PBS-T) for 1 hour while rock-
ing. To wash, blots were rinsed three times and rocked for 20 
minutes in PBS-T. Primary antibodies were applied to blots 
overnight at 4 °C in PBS with 3% BSA (3% BSA-PBS) at 
the following dilutions. A1 (monoclonal mouse anti-VP1 from 
American Research Products, Belmont, MA) was diluted 
1:200; B1 (monoclonal mouse anti-VP1, 2, 3 from Ameri-
can Research Products) diluted 1:50; and mCherry (poly-
clonal rabbit from BioVision, Milpitas, CA) diluted 1:100. After 
washing, goat anti-mouse (Jackson ImmunoResearch, West 
Grove, PA) or rat anti-rabbit (American Research Products) 
peroxidase-conjugated secondary antibodies were applied at 
a 1:2,000 dilution in 5% skim milk in PBS-T for 1 hour. Blots 
were then washed four times for 15 minutes with PBS-T while 
rocking. Imaging was performed on a Fujifilm LAS 4000 after 
applying Lumi-Light western blotting substrate (Roche).
Immunoelectron microscopy. Purified virus samples were 
applied to charged carbon grids (Ted Pella, Redding, CA) for 5 
minutes; wt was adsorbed to a 300 mesh grid with lacey car-
bon type-A (product no. 01890-F), while r1c3 was applied to a 
300 mesh grid with continuous carbon (product no. 01753-F). 
Grids were then blocked for 45 minutes with 3% BSA-PBS, 
washed in 3 drops of PBS and stained with the polyclonal anti-
mCherry antibody (see above) for 1 hour. After washing, gold 
nanoparticle (12 nm) conjugated goat anti-rabbit secondary 
antibodies (Jackson ImmunoResearch) were applied at a 1:30 
dilution in 3% BSA-PBS for 1 hour to visualize mCherry pro-
teins attached to the virions. Samples were then washed and 
negative stained with 0.75% uranylformate to highlight the viral 
capsids before imaging on a JEOL 2010 transmission electron 
microscope operating at 120 kV (JEOL, Tokyo, Japan).
Heparin chromatography. Virus samples were applied to a 
HiTrap heparin-sepharosecolumn (GE Healthcare) equili-
brated with 50 mmol/l Tris-Cl, pH 7.6, 10 mmol/l MgCl2, and 
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150 mmol/l NaCl. Fractionation was performed by passing 
increasing concentrations of NaCl in 1 ml increments and col-
lecting the flow-through. Fractions were quantified by qPCR 
or analyzed by western blot as above.
Confocal microscopy. HeLa cells were seeded onto poly-l-
lysine–coated glass coverslips in a 24-well tissue culture plate 
at a density of 6 × 104 cells per well in phenol-red free Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum and 1% penicillin-streptomycin. The follow-
ing day, r1c3-GFP was applied in serum-free media for 6 hours 
at 37 °C, 5% CO2. Cells were then washed twice with PBS, 
fixed in 4% paraformaldehyde for 15 minutes, washed twice 
and stained with DAPI (1 μg/ml) for 15 minutes. After washing 
twice more in PBS, cells were mounted onto glass slides in 5 μl 
of Fluoromount-G (SouthernBiotech, Birmingham, AL). Sam-
ples were allowed to dry at 4 °C overnight before examination 
on a Zeiss LSM 710. Images were processed using Zen 2010 
software (Carl Zeiss MicroImaging, Jena, Germany).
Transduction assay. HeLa cells were seeded at 1 × 105 cells 
per well in a PLL-coated 24-well tissue culture plate and incu-
bated for 18 hours at 37 °, 5% CO2. Virus samples were diluted 
in serum-free DMEM and added to cells after removing serum-
containing media. Cells were incubated with virus for 4 hours 
at 37 °C, followed by replacement of media to serum-contain-
ing DMEM. Cells were incubated for another 36 hours and 
harvested by trypsin digestion, followed by neutralization with 
serum-containing DMEM. Cells were washed once with PBS 
(5 mmol/l EDTA), passed through a 40 μmol/l cell strainer and 
analyzed on a FACSCanto II flow cytometer (BD Biosciences, 
San Jose, CA). Data was processed using FlowJo software 
(TreeStar, Ashland, OR). Epifluorescent images were taken 
using a Canon EOS Rebel XS camera adapted to a Zeiss 
Axiovert 40 CFL (Carl Zeiss MicroImaging).
Molecular modeling. The r1c3 capsid model was generated 
in SWISS MODEL using the crystal structure AAV2 (PDB# 
1LP3) supplied as a template (Model I) and using the AAV1 
(PDB# 3NG9), mCherry (PDB# 2H5Q), and red fluorescent 
protein (PDB# 3NEZ) when a template was not supplied 
(Model II). Following evaluation of the models in COOT, Model 
II was selected for further analysis because the two compo-
nents of the chimera–the AAV2 VP3 and mCherry structures–
were consistent with this model (Figure 7a). To depict the 
mCherry insertion, which is in VP1 only, in the context of the 
capsid, two options were used. One capsid model was gen-
erated with a unique AAV2-mCherry pentamer  (Figure 7b), 
and the other had five AAV2-mCherry monomers randomly 
assembled on an AAV2 capsid (Figure 7c).
Supplementary Material
Figure S1. Removal of wt genes from pAAV2_RaPID 
library.
Figure S2. Raw flow cytometry data from Figure 6.
Discussion.
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